| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: present group of inventions refers to a method for producing GLU-EGFRvIII conjugate containing a combination of glutamic acid and a linker and enabling glutamic acid and the linker to react throughout the period of time ranging from 30 to 60 minutes; providing a peptide containing SEQ ID NO:1, to an activated product of glutamic acid prepared at the previous stage to produce the GLU-EGFRvIII conjugate; the linker:glutamic acid ratio falls within the range of 75:1 to 325:1, as well as to the GLU-EGFRvIII conjugate produced by the presented method. n EFFECT: group of inventions discloses the effective methods for producing and processes of a therapeutic agent. n 7 cl, 26 dwg, 8 tbl, 7 ex |